Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mobilization of CD34+ cells with standard or reduced dose filgrastim after vinorelbine in multiple myeloma patients
DRKS00003251Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Sep 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of filgrastim in multiple myeloma (MM) (2 arms), sponsored by University of Zurich. Primary endpoint: CD34+ cell mobilization efficacy. Started Sep 2011; status: completed.
02
Drugs
filgrastim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on DRKS00003251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003251.